HAYA Therapeutics, SA, a biotechnology innovator developing groundbreaking RNA-guided programmable precision medicines centered around long non-coding RNAs, is pleased to announce the appointment of Douglas L. Mann, M.D. as Chairperson of its Clinical Advisory Board. Dr. Mann brings a valuable level of expertise and insight to the board, setting the stage for continued success as the company ushers in a new era of advanced healthcare technology.
HAYA Therapeutics is thrilled to welcome Douglas Mann, M.D., as a valued member of the team. With a wealth of experience in the cardiology field, Dr. Mann’s expertise will be integral to advancing HAYA’s lead product candidate, HTX-001, towards clinical trials. HTX-001 is a revolutionary, targeted, RNA-guided programmable therapeutic that has the potential to specifically modify cardiac fibrosis.
Furthermore, HAYA’s cell state modifying platform has the potential to open up opportunities for discovering novel treatments for diseases impacting the liver, lungs, kidneys and the tumor microenvironment. Everyone at HAYA looks forward to working with Dr. Mann and realising the promise of HTX-001.
Dr. Mann is a leading researcher and educator in the field of cardiology, and currently holds the prestigious Ada L. Steininger Professorship in Cardiology at the Washington University School of Medicine in St. Louis. His fascinating body of work focuses on the link between innate immunity and heart failure, and how understanding these connections can improve left ventricular remodeling and reverse left ventricular remodeling.
He has authored nearly 400 peer-reviewed publications for some of the world’s most reputable journals, among them JAMA Cardiology, Circulation, Nature Cardiovascular Research, and the New England Journal of Medicine (NEJM). Furthermore, his research efforts have included herculean efforts as Principal Investigator for various Phase II and III clinical studies aimed at understanding inflammation and cardiac pathology in heart failure patients, including the RENAISSANCE, RENEWAL, Acorn Pivotal Trial, INOVATE-HF and the LIFE trial.
Dr. Mann is one of the most highly decorated and accomplished figures in cardiac care. He was recently honored with the prestigious Lifetime Achievement Award from the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. His impressive academic qualifications include an M.D. from Temple University School of Medicine and a B.A. in Biology from Lafayette College. On top of that, he currently serves as Editor-in-Chief of the esteemed Journal of the American College of Cardiology: Basic to Translational Science. There is no doubt that Dr. Mann is an absolute authority when it comes to cardiac care.
Dr. Mann is thrilled to join forces with HAYA and its mission to develop innovative precision medicines to treat heart failure, starting with HAYA’s very own HTX-001. This targeted fibrosis-modifying therapy specifically targets patients with rare non-obstructive hypertrophic cardiomyopathy (HCM), who are limited in their available treatment options. What truly sets HTX-001 apart is its unique properties which may render it applicable in a variety of other cardiac indication, thus revolutionizing the way we treat heart failure.
About HAYA Therapeutics
HAYA Therapeutics is revolutionizing healthcare through precision medicine, harnessing the power of the dark genome to reprogram pathological cell states and develop therapeutic treatments for a multitude of conditions, including cardiovascular disease and cancer. At the cutting edge of medical technology, the company’s innovative platform is unlocking new insights into how cellular biology influences disease.
Led by their flagship therapeutic candidate HTX-001, targeting Wisper, a heart-specific lncRNA known to be associated with cardiac fibrosis, HAYA is set on discovering precision therapies to treat disease in other areas of the body, from the lungs to the tumor microenvironment.
HAYA’s vision is to revolutionize the field of medicine with its programmable and precision RNA-targeted therapeutics. Situated at the Biopôle life sciences park in Lausanne, Switzerland and with laboratory access at JLABS @ San Diego, HAYA is composed of a renowned team of leading experts in the field who are supported by a strong network of investors. Driven to identify and develop breakthrough treatments that can offer greater efficacy, safety, and accessibility than what is available today, HAYA is striving to revolutionize the future of medicine.